Biological Weapon Francisella Tularensis Direct Fluorescent Antibody High Case Fatality Rate Public Health Management 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Dennis DT, Inglesby TV, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Fine AD, Friedlander AM, Hauer J, Layton M, Lillibridge SR, McDade JE, Osterholm MT, O’Toole T, Parker G, Perl TM, Russell PK, Tonat K. 2001. Tularemia as a biological weapon: medical and public health management. JAMA 285:2763–2773.PubMedCrossRefGoogle Scholar
  2. Franz DR, Jahrling PB, McClain DJ, Hoover DL, Byrne WR, Pavlin JA, Christopher GW, Cieslak TJ, Friedlander AM, Eitzen EM Jr. 1997. Clinical recognition and management of patients exposed to biological warfare agents. JAMA 278:339–411.CrossRefGoogle Scholar
  3. Kaufmann AF, Meltzer MI, Schmid GP. 1997. The economic impact of a bioterrorist attack: are prevention and postattack intervention programs justifiable? Emerg Infect Dis 3:83–94.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science +Business Media, LLC 2006

Authors and Affiliations

  • Tracy H. Zivin-Tutela
    • 1
  1. 1.Division of Infectious Diseases, St. Luke’s/Roosevelt Hospital CenterNew York

Personalised recommendations